For your symptomatic patients with COPD,

It’s Not Too Early to Start With BREZTRI1-3

Impact of Exacerbations

Impact of Exacerbations

Every exacerbation can have far-reaching consequences for your patients4-6

Learn More Now
Safety Icon

Safety Profile

Review Important Safety Information and adverse reactions

View the Safety Profile
Access and Formulary

Access and Formulary

Quickly find coverage for BREZTRI in your area

Prescribe Confidently

Important Safety Information

Important Safety Information

+

References
  • 1. BREZTRI AEROSPHERE [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022.

  • 2. Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial [article and supplementary appendix]. Lancet Respir Med. 2018;6(10):747-758.

  • 3. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD [article and supplementary appendix]. N Engl J Med. 2020;383(1):35-48.

  • 4. Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017;128:85-91.

  • 5. Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51-57.

  • 6. Lindenauer PK, Dharmarajan K, Qin L, Lin Z, Gershon AS, Krumholz HM. Risk trajectories of readmission and death in the first year after hospitalization for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(8):1009-1017.